Arkadios Wealth Advisors Boosts Stock Position in GSK plc (NYSE:GSK)

Arkadios Wealth Advisors increased its holdings in GSK plc (NYSE:GSK – Get Rating) by 0.5% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 63,636 shares of the pharmaceutical company’s stock after acquiring an additional 308 shares during the period. Arkadios Wealth Advisors’ holdings in GSK were worth $1,554,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Pflug Koory LLC purchased a new position in GSK in the third quarter worth approximately $26,000. Nelson Van Denburg & Campbell Wealth Management Group LLC grew its position in GSK by 61.3% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 968 shares of the pharmaceutical company’s stock worth $42,000 after acquiring an additional 368 shares during the period. Householder Group Estate & Retirement Specialist LLC purchased a new position in GSK in the third quarter worth approximately $31,000. Accurate Wealth Management LLC purchased a new position in GSK in the fourth quarter worth approximately $46,000. Finally, CoreCap Advisors LLC purchased a new position in GSK in the second quarter worth approximately $66,000. 13.15% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. StockNews.com began coverage on GSK in a research report on Thursday. They issued a “buy” rating for the company. Deutsche Bank Aktiengesellschaft upgraded GSK from a “hold” rating to a “buy” rating in a research note on Friday. Morgan Stanley decreased their price target on GSK from GBX 1,650 ($20.11) to GBX 1,535 ($18.71) in a research note on Wednesday, November 30th. The Goldman Sachs Group began coverage on GSK in a research note on Sunday, February 26th. They set a “buy” rating on the stock. Finally, Bank of America cut GSK from a “neutral” rating to an “underperform” rating in a research note on Monday, December 5th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $1,576.88.

GSK Stock Up 0.7 %

Shares of NYSE GSK opened at $34.07 on Friday. The stock has a market cap of $73.44 billion, a P/E ratio of 3.97, a PEG ratio of 1.70 and a beta of 0.65. The company has a current ratio of 0.91, a quick ratio of 0.68 and a debt-to-equity ratio of 1.69. GSK plc has a 12-month low of $28.47 and a 12-month high of $46.97. The business’s fifty day simple moving average is $35.00 and its 200-day simple moving average is $33.57.

GSK Cuts Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 13th. Stockholders of record on Friday, February 24th will be paid a $0.3404 dividend. This represents a $1.36 annualized dividend and a dividend yield of 4.00%. The ex-dividend date of this dividend is Thursday, February 23rd. GSK’s payout ratio is currently 15.50%.

GSK Company Profile

(Get Rating)

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation.